| Followers | 277 |
| Posts | 13764 |
| Boards Moderated | 0 |
| Alias Born | 02/17/2014 |
Thursday, May 25, 2017 9:27:08 AM
**TOP REASONS TO BUY CBAI NOW**
Cord Blood America (CBAI) is the MOST Undervalued Biotech EVER:
Buy as many shares as you can because the current sub-penny share price
won't last long!
Cord Blood America (CBAI) is a global leader in cord tissue stem cell services!
Here is the extremely amazing VALUE for investors, the share price of CBAI closed at .0039 on May 24 2017.
It is INCREDIBLY undervalued, a very rare find, a biotech penny stock generating millions in revenues yet has almost no debt and had no dilution for years!
In fact CBAI in SEC filings for the period ended March 31st 2017 posted revenues of
$745 948 on track to post over $3 MILLION in revenues for 2017 and had a POSITIVE cash flow!
Yet amazingly CBAI has remained under the radar trading near historic lows! Now is the time to buy shares of what is clearly the MOST UNDERVALUED BIOTECH STOCK across all markets!
Cord Blood America (CBAI) through its CorCell™ program and its wholly owned subsidiary CorCell Companies, provides cord blood and cord tissue stem cell services.
Cryogenically preserved cord blood stem cells have already been used to treat 80 major diseases, including leukemia, severe anemia, metabolic and blood disorders and immune deficiencies.
In addition, the umbilical cord, which at birth traditionally has been thrown away, contains a rich store of stem cells
Cord Blood America (CBAI): Highlights, Due Diligence and Speculation
-CBAI is now cash flow positive
-CBAI has eliminated virtually all debt
-CBAI has almost ONE MILLION dollars in the bank, flush with cash!
-CBAI is on track to post over $3 MILLION in revenues for 2017
-CBAI has assets of $2.8 MILLION
-CBAI has big time Wall Street backing, Red Oak Partners are a major SEC investment group who work closely with Goldman Sachs. They own 381 million shares and control the BOD
-CBAI and big pharma Pfizer (PFE) have begun working together, CBAI meets the highest ethical standards that PFE demands with regards to stem cells and also have experience with currently-available, human embryonic stem cell lines
-CBAI is highly likely to be acquired by Pfizer (PFE) in 2017 as big pharmas race to dominate the multi billion stem cell market
-CBAI has a 6 month short term price target of 50 cents
-CBAI has a long term price target of $2-3 per share upon buyout
-CBAI is currently THE MOST UNDERVALUED BIOTECH stock trading in the sub-penny range
LINKS:
Cord Blood America (CBAI) wholly owned subsidiary CorCell
© 2017 CorCell. All rights reserved, CorCell Companies, Inc. A Cord Blood America Company
https://www.corcell.com/
Red Oak Partners
A major WALL Street SEC investment group who work closely with Goldman Sachs
https://redoakpartners.com
More about Cord Blood America (CBAI)
CBAI is a biotechnology company that offers stem cell storage services. The company provides cord blood and cord tissue stem cell services. It collects, tests, processes and preserves umbilical cord blood at the birth of a child for potential use in future stem cell therapy. CBAI's preserved cord blood stem cells have been used to treat various diseases such as leukemia, severe anemia, metabolic and blood disorders and immune deficiencies. The company operates through its laboratory located in Las Vegas. It operates in New York, New Jersey, California, and Maryland. CBAI is headquartered in Las Vegas, Nevada, the US.
Our Laboratory
You can rest assured that your customer’s umbilical cord blood is being processed and stored using the utmost care and highest industry standards. Our state of the art laboratory is located minutes from McCarran International Airport in Las Vegas, NV; with approximately 3,300 inbound flights per week we are able to receive your customer’s samples 24/7/365. We are a fully licensed cord blood bank that has processed more than 27,000 cord blood units since first opening in 1996. Our 17,000-square-foot facility is equipped with the most advanced processing and storage technologies. The facility is under 24 hour surveillance with stringent restricted access protocols your client’s cord blood unit will be kept at the correct temperature at all times thanks to our 24 hour monitoring system.
CBAI offers extensive experience, with over 16 years in the cord blood banking industry, a proven processing model, technology and all the assistance our business to business clients need to grow their cord blood banking company without the additional cost of operating their own laboratory. CBAI is licensed in New Jersey, New York, California and Maryland and registered with the FDA. We are also a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.
Cord Blood America (CBAI) is the MOST Undervalued Biotech EVER:
Buy as many shares as you can because the current sub-penny share price
won't last long!
Cord Blood America (CBAI) is a global leader in cord tissue stem cell services!
Here is the extremely amazing VALUE for investors, the share price of CBAI closed at .0039 on May 24 2017.
It is INCREDIBLY undervalued, a very rare find, a biotech penny stock generating millions in revenues yet has almost no debt and had no dilution for years!
In fact CBAI in SEC filings for the period ended March 31st 2017 posted revenues of
$745 948 on track to post over $3 MILLION in revenues for 2017 and had a POSITIVE cash flow!
Yet amazingly CBAI has remained under the radar trading near historic lows! Now is the time to buy shares of what is clearly the MOST UNDERVALUED BIOTECH STOCK across all markets!
Cord Blood America (CBAI) through its CorCell™ program and its wholly owned subsidiary CorCell Companies, provides cord blood and cord tissue stem cell services.
Cryogenically preserved cord blood stem cells have already been used to treat 80 major diseases, including leukemia, severe anemia, metabolic and blood disorders and immune deficiencies.
In addition, the umbilical cord, which at birth traditionally has been thrown away, contains a rich store of stem cells
Cord Blood America (CBAI): Highlights, Due Diligence and Speculation
-CBAI is now cash flow positive
-CBAI has eliminated virtually all debt
-CBAI has almost ONE MILLION dollars in the bank, flush with cash!
-CBAI is on track to post over $3 MILLION in revenues for 2017
-CBAI has assets of $2.8 MILLION
-CBAI has big time Wall Street backing, Red Oak Partners are a major SEC investment group who work closely with Goldman Sachs. They own 381 million shares and control the BOD
-CBAI and big pharma Pfizer (PFE) have begun working together, CBAI meets the highest ethical standards that PFE demands with regards to stem cells and also have experience with currently-available, human embryonic stem cell lines
-CBAI is highly likely to be acquired by Pfizer (PFE) in 2017 as big pharmas race to dominate the multi billion stem cell market
-CBAI has a 6 month short term price target of 50 cents
-CBAI has a long term price target of $2-3 per share upon buyout
-CBAI is currently THE MOST UNDERVALUED BIOTECH stock trading in the sub-penny range
LINKS:
Cord Blood America (CBAI) wholly owned subsidiary CorCell
© 2017 CorCell. All rights reserved, CorCell Companies, Inc. A Cord Blood America Company
https://www.corcell.com/
Red Oak Partners
A major WALL Street SEC investment group who work closely with Goldman Sachs
https://redoakpartners.com
More about Cord Blood America (CBAI)
CBAI is a biotechnology company that offers stem cell storage services. The company provides cord blood and cord tissue stem cell services. It collects, tests, processes and preserves umbilical cord blood at the birth of a child for potential use in future stem cell therapy. CBAI's preserved cord blood stem cells have been used to treat various diseases such as leukemia, severe anemia, metabolic and blood disorders and immune deficiencies. The company operates through its laboratory located in Las Vegas. It operates in New York, New Jersey, California, and Maryland. CBAI is headquartered in Las Vegas, Nevada, the US.
Our Laboratory
You can rest assured that your customer’s umbilical cord blood is being processed and stored using the utmost care and highest industry standards. Our state of the art laboratory is located minutes from McCarran International Airport in Las Vegas, NV; with approximately 3,300 inbound flights per week we are able to receive your customer’s samples 24/7/365. We are a fully licensed cord blood bank that has processed more than 27,000 cord blood units since first opening in 1996. Our 17,000-square-foot facility is equipped with the most advanced processing and storage technologies. The facility is under 24 hour surveillance with stringent restricted access protocols your client’s cord blood unit will be kept at the correct temperature at all times thanks to our 24 hour monitoring system.
CBAI offers extensive experience, with over 16 years in the cord blood banking industry, a proven processing model, technology and all the assistance our business to business clients need to grow their cord blood banking company without the additional cost of operating their own laboratory. CBAI is licensed in New Jersey, New York, California and Maryland and registered with the FDA. We are also a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.
Everything I say is just my opinion, I am not a registered financial adviser, please consult one before investing in any stock based upon anything you may read in my comments!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
